I read with great interest the recent review by Shi [1] regarding the intricate relationship between the stria vascularis (SV) microvasculature and the innate immune system in the context of age related hearing loss (ARHL). While the author provides a masterful overview of the Blood-Labyrinth Barrier, I believe certain critical physiological omissions merit further discussion, as they may fundamentally alter our approach to future therapeutic interventions.

A primary concern involves the “chicken and egg” paradox regarding ionic homeostasis versus vascular-driven immunosenescence. While SV degradation is traditionally linked to macrophage recruitment, contemporary evidence suggests that primary shifts in endocochlear potential and potassium recycling may precede and trigger the PVM/Ms-mediated inflammatory response. Distinguishing whether inflammation is the driver or a secondary byproduct of metabolic exhaustion is vital for determining the clinical timing of antiinflammatory versus metabolic-stabilizing therapies [2].

Furthermore, the review treats “inflammaging” as a monolithic phenomenon, largely overlooking the significant role of sex dimorphism in cochlear immunosenescence. Estrogen receptors are prominently expressed within the SV, and clinical data consistently demonstrate different trajectories of metabolic presbycusis between sexes. Ignoring sex as a critical biological variable in the “immunological barrier” discussion risks the development of standardized therapeutic targets that may fail in sex-stratified clinical trials [3].

Of equal importance is the transition of cellular phenotypes within the stria. While pericyte loss is discussed, the potential for Pericyte-to-Myofibroblast Transition remains unaddressed. In the aging microenvironment, pericytes do not simply disappear; they often undergo transdifferentiation into profibrotic cells, leading to irreversible structural remodeling and basement membrane thickening. Identifying this phenotypic shift as a “point of no return” is essential for refining the therapeutic window for ARHL [4].

These considerations do not diminish the value of Shi’s review but rather suggest that the cochlear microenvironment is even more dynamic and potentially more gender- and stage-dependent than presented. I welcome the author’s perspective on these nuances.